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Bacterial strains passaged in the laboratory have lost several phenotypes that are readily observable with "wild" or undomesticated strains ([@B1][@B2][@B3]). *Bacillus subtilis* strain NCIB 3610 (abbreviated as 3610) is a derivative of Marburg with genomic similarity to *B. subtilis* 168 ([@B4]). Undomesticated 3610 forms multicellular structures with complex architecture and cell organization ([@B1], [@B2]). Pellicle biofilms, swarming motility, exopolysaccharide capsule, surfactant, and the production of antimicrobials are just a few examples of the many phenotypes that have been lost from laboratory strains ([@B4][@B5][@B9]). In addition to the differences in phenotypes, 3610 also harbors an 84 kb plasmid (pBS32) that has been cured from domesticated strains. Plasmid pBS32 encodes 102 genes including *comI*, the product of which is an inhibitor that prevents 3610 from developing genetic competence ([@B10]). The recent identification of ComI as a genetic competence inhibitor allowed for the generation of the naturally competent 3610 *comI*^Q12L^ (DK1042) strain, facilitating genetic study of the complex phenotypes associated with undomesticated strains ([@B10]). To further expedite genetic studies, we report the completed reference genome for DK1042, where the *comI*^Q12L^ point mutation is the only known mutation in an otherwise 3610 genetic background. Our results provide a publicly available complete reference genome for a competent 3610 derived strain, helping to forward the use of 3610 as a genetic platform for studying phenotypes and behaviors not present in domesticated laboratory strains.

Genomic DNA from DK1042 (NCIB 3610 *comI*^Q12L^) ([@B10]) was purified via phenol-chloroform extraction ([@B11]). Sequencing libraries were prepared with 5-kb mean insert size for sequencing on the Pacific Biosciences (PacBio) RS II sequencer by the University of Michigan Sequencing Core. Two single-molecule real-time cells were used to sequence the libraries. The average subread length was 3.5 kb. *De novo* genome assembly was performed using RS_HGAP_Assembly.3 version 2.3.0 ([@B12]), resulting in two contigs representing the chromosome and plasmid (pBS32). A break was introduced at the chromosomal origin *in silico* and the genome was circularized using the minimus2 script from AMOS ([@B13]). The original PacBio sequencing reads were remapped to the circularized reference genome via RS_Resequencing.1, resulting in a consensus accuracy of 99.9997% and chromosomal coverage of 625. The previously sequenced pBS32 plasmid sequence \[accession no. KF365913 ([@B10])\] was then added as a second contig to create the final NCIB 3610 *comI*^Q12L^ reference genome. The final reference genome consists of a 4,215,607 bp chromosome and 84,215 bp plasmid. The 2 contigs have a combined length of 4,299,831 bp. The previous reference genome for NCIB 3610 totaled 4,292,969 bp (chromosome and plasmid) and consisted of 84 contigs ([@B14]). Thus, the reference genome presented here has reduced the number of contigs from 84 to 2, with a 6.8 kb longer sequenced genome size.
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Gene annotation was performed using the Prokaryotic Genomes Annotation Pipeline (PGAP) through NCBI. The complete genome sequence of *B. subtilis* subsp. *subtilis* strain NCIB 3610 *comI*^Q12L^ was deposited in the DDBJ/EMBL/GenBank database with accession no. [CP020102](https://www.ncbi.nlm.nih.gov/nuccore/CP020102) for the chromosome and [CP020103](https://www.ncbi.nlm.nih.gov/nuccore/CP020103) for pBS32 ([@B10]).
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